

CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05%- clindamycin 1% / niacinamide 2% / tazarotene 0.05% gel

Sincerus Florida, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, [click here](#).

CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05%

Directions for use



Directions for use

As directed by Physician.
Apply topically. For external use only. Wash hands after use.
Store at controlled room temperature (20-25C).

Sincerus Florida, LLC (800) 604-5032
3265 W McNab Rd, Pompano Beach, FL 33069
To report suspected adverse reactions, contact
Sincerus Florida, LLC at (800) 604-5032, or FDA
at www.FDA.gov/MedWatch or (800) FDA-1088.
Office use only. Not for resale.



Sincerus Florida, LLC. Adverse reactions



Directions for use

As directed by Physician.

Apply topically. For external use only. W
Store at controlled room temperature (2

Sincerus Florida, LLC (800

3265 W McNab Rd, Pompano Beach

To report suspected adverse reactions
Sincerus Florida, LLC at (800) 604-503

at www.FDA.gov/MedWatch or (800) F

Office use only. Not for resal



Active, inactive




**NDC 72934-1050-2 CLINDAMYCIN PHOSPHATE USP 1% / NIACINAMIDE USP 2% /
TAZAROTENE 0.05%. Gel 30gm**



Rx only
NDC 72934-1050-2

NDC 72934-1050-2
CLINDAMYCIN PHOSPHATE
USP 1%
NIACINAMIDE USP 2%



CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05%

clindamycin 1% / niacinamide 2% / tazarotene 0.05% gel

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:72934-1050
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
TAZAROTENE (UNII: 81BDR9Y8PS) (TAZAROTENE - UNII:81BDR9Y8PS)	TAZAROTENE	0.05 g in 100 g
NIACINAMIDE (UNII: 25X51I8RD4) (NIACINAMIDE - UNII:25X51I8RD4)	NIACINAMIDE	2 g in 100 g
CLINDAMYCIN PHOSPHATE (UNII: EH6D7113I8) (CLINDAMYCIN - UNII:3U02EL437C)	CLINDAMYCIN PHOSPHATE	1 g in 100 g

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:72934-1050-2	30 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product	05/10/2019	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		05/10/2019	

Labeler - Sincerus Florida, LLC (080105003)**Establishment**

Name	Address	ID/FEI	Business Operations
Sincerus Florida, LLC		080105003	manufacture(72934-1050)

Revised: 5/2019

Sincerus Florida, LLC